Johnson & Johnson’s antipsychotic drugs Risperdal, Risperdal Consta and Invega made billions of dollars for the company, but they are linked to serious side effects like breast development in boys (called gynecomastia) and movement disorders such as tardive dyskinesia. J&J already paid millions to the government for improperly marketing Risperdal, and now it faces lawsuits filed by patients. Patriot’s generic risperidone is also linked to these side effects.
What are Risperdal and Invega?
Risperdal (risperidone) and Invega (paliperidone) are powerful second-generation antipsychotics approved for the treatment of schizophrenia in adults and adolescents and are both manufactured by Johnson & Johnson’s Janssen Pharmaceuticals unit. Risperdal is also approved to treat bipolar disorder in adults and adolescents, and autism spectrum disorders in children and adolescents. Invega is also approved to treat schizoaffective disorder.
Risperdal is also available in a long-acting injection called Risperdal Consta. J&J also released authorized generic risperidone though another of its subsidiaries, Patriot.